What is Ocular Science?
Headquartered in El Segundo, California, Ocular Science operates at the intersection of medical innovation and patient-centric design. Since its inception in 2015, the company has distinguished itself by developing affordable, paradigm-shifting products tailored for the corrective eye care industry. Supported by a distinguished medical advisory board of 30 ophthalmology experts, the organization focuses on enhancing patient compliance and clinical outcomes. Their business model prioritizes the delivery of user-friendly, cost-effective solutions that address the evolving needs of both physicians and patients, effectively disrupting traditional market standards in ocular health.
How much funding has Ocular Science raised?
Ocular Science has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Ocular Science
PPP
Public-Private Partnership
What's next for Ocular Science?
With this late-stage capital, Ocular Science is poised to scale its operational infrastructure and expand its market reach. The strategic allocation of these funds will likely focus on deepening the company's research and development pipeline, ensuring that their therapeutic offerings remain at the forefront of ophthalmological science. As the firm transitions into this next phase of growth, the focus will remain on optimizing supply chain efficiencies and broadening the distribution of their corrective eye care portfolio. By maintaining a rigorous commitment to clinical excellence and cost-efficiency, Ocular Science is set to solidify its role as a key player in the global biotech ecosystem, driving long-term value for stakeholders and improving quality of life for patients worldwide.
See full Ocular Science company page
